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Edited by Ulrike KutayAbstract 1,25-Dihydroxyvitamin D3 (1,25D) regulates gene
transcription through the nuclear vitamin D receptor (VDR)
and initiates rapid cellular responses via an unknown mechanism.
Here we report that 1,25D induces a rapid increase in synthesis
of VDR protein and its transport to the nucleus. These results
are similarly obtained in myeloid leukemia cell lines, and in blast
cells from blood of patients diagnosed with acute myeloid leuke-
mia, subtypes M2 and M4. Our results suggest that stability of
unliganded VDR is LY294002- and PD98059-dependent, and
that ligation of VDR leads to its increased translation and nucle-
ar translocation. The receptor localized in the cell nucleus is not
exported back to the cytosol by exportin 1. We also show that
the cytosolic portion of VDR in leukemia cells is localized in
the vicinity of the plasma membrane, close to the F-actin cyto-
skeleton.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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leukemia1. Introduction
1,25-Dihydroxyvitamin D3 (1,25D) is a pleiotropic hor-
mone, which regulates calcium homeostasis of the organism,
induces diﬀerentiation and inhibits proliferation of various
normal and cancer cells, including osteoclasts, keratinocytes
and monocytes [1–3]. Even though the precise molecular basis
of leukemia cell diﬀerentiation triggered by 1,25D is unclear, it
is known that the major regulator of the biological activity of
1,25D is the nuclear vitamin D receptor (VDR) which can
form homodimers [4], and the physiologically more active het-
erodimers with retinoid X receptor (RXR) [5,6]. Binding of the
1,25D enhances VDR/RXR heterodimerization and allows for
the association with speciﬁc DNA sequence named the vitaminAbbreviations: 1,25D, 1,25-dihydroxyvitamin D3; VDR, vitamin D
receptor; RXR, retinoid X receptor; VDRE, vitamin D response ele-
ment; DRIP, vitamin D receptor-interacting protein complex; PKC,
protein kinase C; PI3-kinase, phosphatidylinositol 3-kinase; MAPK,
mitogen activated protein kinase; ER, estrogen receptor; FCS, fetal
calf serum; PBS, phosphate-buﬀered saline; KSR, kinase suppressor of
Ras
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RXR and 1,25D binds to the VDRE and acts as a ligand-
dependent transcription factor. This activated complex then
recruits a coactivator complex, known as vitamin D recep-
tor-interacting protein complex (DRIP) [7] and other proteins,
histone acetylase among them. Acetylated histones relax chro-
matin structure to make DNA accessible and permit initiation
of transcription of the target gene [8]. But it is also known that
1,25D activates some intracellular signaling pathways, so
called ‘‘rapid’’ cellular responses [9]. It has been reported that
these include the protein kinase C (PKC) pathway, calcium-
dependent pathway, phosphatidylinositol 3-kinase (PI3-ki-
nase) pathway and three groups of mitogen activated protein
kinases (MAPKs) [10]. It is not clear at the moment if
1,25D-induced activation of the signal transduction pathways
results in any modiﬁcations of VDR protein. It has not been
well documented if VDR can be phosphorylated by Erk1,2 ki-
nases, despite some data point at it [11]. Moreover, there are
some data, which show that in response to 1,25D treatment
VDR interacts with PI3-kinase and Src kinase [12–14]. The
fact that activation of PI3-kinase is very important for
1,25D-induced diﬀerentiation has been known for some years
[15], and it was later shown that 1,25D activates PI3-kinase
[12] and its downstream element Akt kinase in the target cells
[16,17]. Also activation of Src kinase has been documented in
diﬀerent cell line models [18,19]. How are activations of Src
and PI3-kinase and their physical interactions with VDR con-
nected is not known at the moment, but some lessons can be
learnt from the estrogen receptor (ER) studies. Many biologi-
cal eﬀects of estrogens require activation of Src and PI3-ki-
nases [20–22]. It has been documented that in breast cancer
cells, which are responsive to estrogens, liganded ER forms
stable ternary complex with Src kinase and with the regulatory
domain of PI3-kinase, p85 [23]. Without liganded ER, the
complex consisting of p85 and Src is unstable. Both ER and
VDR belong to the superfamily of steroid receptors, which
act as ligand dependent transcription factors. Thus in order
to be active, these receptors must enter the cell nucleus. Intra-
cellular localization of VDR has been an issue of some contro-
versies since it is not fully agreed if VDR is translocated to the
cell nucleus in response to 1,25D [24], or if it continuously
shuttles between cytosol and nucleus and 1,25D traps it inside
the cell nucleus [25]. It has been shown that the expression of
VDR in the cells increases in response to 1,25D [26], however
not in every type of target cells [27]. Thus in this study we
wanted to ﬁnd out if activation of PI3-kinase is important
for expression and nuclear translocation of VDR in 1,25D-
treated myeloid leukemia cells. For comparison we addressedblished by Elsevier B.V. All rights reserved.
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p38 pathway. In our studies we used two cell lines HL60 and
THP-1. HL60 cells originate from acute myeloid leukemia sub-
type M2 [28], while THP-1 cells from acute myeloid leukemia
subtype M5 [29] and both cell lines are responsive to 1,25D. In
order to validate that the observations are not limited to the
cell lines, we used in part of our studies blast cells isolated from
blood of freshly diagnosed patients with acute myeloid leuke-
mia.2. Materials and methods
2.1. Cell lines
HL60 and THP-1 cells were obtained from the European Collection
of Cell Cultures. These cells were propagated as a suspension culture in
RPMI 1640 medium supplemented with 10% fetal calf serum (FCS,
Sigma, St. Louis, MO), 100 units/ml penicillin and 100 lg/ml strepto-
mycin (Sigma, St. Louis, MO). The cells were kept at standard cell cul-
ture conditions, i.e. humidiﬁed atmosphere of 95% air and 5% CO2 at
37 C. The cell number and viability were determined by hemocytom-
eter counts and trypan blue (0.4%) exclusion. For all experiments the
cells were suspended in fresh medium containing 1,25D or the equiva-
lent volume of ethanol as a vehicle control.
2.2. Isolation of mononuclear cells from patient’s peripheral blood
Ten milliliters of peripheral blood was diluted with phosphate-buf-
fered saline (PBS) in 1:1 ratio. Diluted blood was carefully layered
onto the equal volume of Histopaque-1077, and then was centrifuged
at 400·g for 30 min. The opaque interface was carefully transferred
into new, sterile tube, and washed three times with PBS. Then the cells
were transferred to RPMI 1640 medium supplemented with 10% FCS,
100 units/ml penicillin and 100 lg/ml streptomycin and kept at stan-
dard cell culture conditions.2.3. Chemicals and antibodies
1,25D was a kind gift from Dr. Peter Weber (Hoﬀmann-La Roche
S.A., Pharma Preclinical Research, Basel, Switzerland). PD98059
and LY294002 were from Calbiochem (San Diego, CA). Leptomycin
B was from LC Laboratories (Boston, MA). Chemiluminescence Blot-
ting Substrate was from Roche Diagnostics (Mannheim, Germany).
Mouse monoclonal anti-VDR and rabbit polyclonal anti-ERa were
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Goat anti-rab-
bit IgG and anti-mouse IgG conjugated to peroxidase or to RD1 were
from Jackson ImmunoResearch (West Grove, PA). All other reagents
were from Sigma (St. Louis, MO).2.4. Cell fractionation
Cell fractionation was performed as previously described [29]. The
cells were washed three times with PBS, and lysed for 20 min on ice
in lysis buﬀer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100; pH 7.5) containing protease inhibitor cock-
tail. The lysates were separated by centrifugation for 5 min, at
14000 rpm, at 4 C. Supernatants were designated the cytoplasmatic
fraction and the nuclei remaining in pellets after one washing were son-
icated for 10 s in a new portion of lysis buﬀer. After sonication nuclei
were centrifuged again and the ﬁnal supernatants were designated the
nuclear fraction.
In order to separate cytosol from membranes, the cells after treat-
ment were washed three times with PBS and afterwards incubated in
Hepes medium containing 20 lg/ml of digitonin and protease inhibitor
cocktail for 5 min at room temperature and for 30 min on ice. After
5 min centrifugation at 3000 rpm, at 4 C the supernatant was collected
and designated the cytosolic fraction. The remaining pellets were lysed
for 20 min on ice in lysis buﬀer containing protease inhibitor cocktail.
The lysates were separated by centrifugation for 5 min, at 14000 rpm,
at 4 C. Here the supernatants were designated the membrane fraction
and the nuclei remaining in pellets after one washing were sonicated
for 10 s in a new portion of lysis buﬀer. After sonication nuclei were
centrifuged again and the ﬁnal supernatants were designated the nucle-
ar fraction.2.5. Western blotting
For Western blotting 25 ll of protein samples were separated on
12% SDS–PAGE gel and transferred to PVDF membranes. The mem-
branes were dried, then blotted with primary antibodies for 1 hour at
room temperature, washed three times with TBS and then blotted with
horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h
at room temperature. The protein bands were visualized with a chemi-
luminescence assay system. Then the membranes were stripped, dried
again and probed with subsequent antibodies. Each experimental con-
dition was repeated at least twice.2.6. Confocal microscopy
Coverslips were coated with poly-L-lysine solution just before the
cells were seeded. The cells were treated as required and then they were
ﬁxed in 3% paraformaldehyde for 30 min at room temperature. The
cells were then permeabilized with 0.1% Triton X-100 in PBS for
5 min. VDR was detected by incubating the samples with mouse
anti-VDR (1:100) for 20 min. After three washes in PBS the samples
were incubated with anti-mouse secondary antibodies conjugated to
RD1 for 20 min and phalloidin conjugated to FITC and washed again.
The speciﬁcity of staining was veriﬁed by omitting VDR staining in the
procedure. Coverslips were ﬁnally mounted onto glass slides using
Mowiol and the samples were analyzed with a Zeiss LSM 510 META
confocal microscope (Thornwood, NY).3. Results and discussion
3.1. Expression and nuclear translocation of VDR is an early
response to 1,25D in leukemia cells
It has been shown in past that inhibitors of intracellular sig-
naling pathways inﬂuence cell diﬀerentiation eﬀect of 1,25D in
myeloid leukemia cells. These observations have been de-
scribed for HL60 and THP-1 cell lines. When inhibitors of
MAPK/Erk1,2 signal transduction pathway and inhibitors of
PI3-kinase have been added to the cells simultaneously with
1,25D, cell diﬀerentiation was markedly inhibited in compari-
son with the eﬀect of 1,25D alone [12,15,30–33]. Since diﬀerent
MAPK pathways compose feedback loops in myeloid cells,
inhibition of MAPK/p38 pathway resulted in an enhanced ef-
fect of 1,25D-induced cell diﬀerentiation [10,34]. An appear-
ance of cell diﬀerentiation markers is a relatively late event
in 1,25D initiated processes in leukemia cells, so we wanted
to ﬁnd an earlier eﬀect of 1,25D. For this part of our experi-
ments we applied cell fractionation method, which allows sep-
aration of cytosol and membranes from cell nuclei, in order to
determine localization of VDR in further experiments. We ob-
served that the increase in expression of VDR protein and its
translocation to the cell nucleus could be detected as early as
1 h after treatment of the cells with 10 nM 1,25D. In untreated
cells the intracellular level of VDR was relatively low, with lit-
tle nuclear content (Fig. 1a). After 1 h of treatment the expres-
sion was higher and predominantly nuclear and it persisted
until the late steps of cell diﬀerentiation (not shown here). It
is noteworthy that similar upregulation and nuclear transloca-
tion of VDR could be observed in blast cells from myeloid leu-
kemias in ex vivo cultures. In our experiments blast cells were
isolated from blood of freshly diagnosed patients with acute
myeloid leukemias, subtypes M2 and M4. The cells were ex-
posed to 1,25D for 3 h and then the cells were collected and
fractionated as above. As presented in Fig. 1b and c, nuclear
content of VDR increased in comparison with control cells,
however susceptibility of the cells to 1,25D diﬀered between
patients, and possibly was related to the subtype of acute mye-
loid leukemia.
Treatment control 10nM1,25D-1h 
10nM 
1,25D-2h 
Fraction C/M N C/M N C/M N
Lane 1 2 3 4 5 6
VDR →
β-actin →
Treatment control 100nM 1,25D 
Fraction C/M N C/M N
Lane 1 2 3 4
VDR → 
β-actin → 
Treatment control 10nM 1,2D
Fraction C/M N C/M N
Lane 1 2 3 4
VDR → 
β-actin →
a
b
c
Fig. 1. Kinetics of expression and nuclear translocation of VDR.
HL60 cells (a) were treated with 10 nM 1,25D for indicated times.
Blast cells isolated from blood of patients with freshly diagnosed
AML-M2 (b) and AML-M4 (c) were treated for 3 h with 1,25D in
indicated concentrations. The cells were fractionated into cytoplasm
(C/M) and nuclei (N). VDR and b-actin were detected in Western
blotting.
Treatment control 10nM 1,25D CHX+1,25D
Fraction C/M N C/M N C/M N
Lane 1 2 3 4 5 6
VDR →
β-actin →
VDR →
β-actin →
Fig. 2. Cycloheximide-dependent increase in nuclear VDR. HL60
(upper blots) and THP-1 (lower blots) cells were treated for 2 h with
10 nM 1,25D. One sample was preincubated with 10 lg/ml of
cycloheximide (CHX) for 1 h before addition of 1,25D. The cells were
fractionated into cytoplasm (C/M) and nuclei (N). b-Actin was
detected as a loading and transfer control.
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1 cells is protein synthesis-dependent
Even though from the visual inspection of the above results
it seemed obvious that exposure to 1,25D induced synthesis of
VDR protein in the cells, we wanted to verify this observation
using biochemical methods. For this purpose the cells were
preincubated for 1 h with protein translation inhibitor, and
then treated with 10 nM 1,25D for next 2 h. The fact that nu-
clear appearance of VDR was almost completely abolished by
cycloheximide (Fig. 2) conﬁrms the observation that a substan-
tial portion of VDR present in cells after treatment with 1,25D
comes from de novo synthesis.
3.3. LY294002 and PD98059 inhibit expression and nuclear
translocation of VDR in HL60 and THP-1 cells
In the next experiments we wanted to test, whether 1,25D in-
duced synthesis and nuclear translocation of VDR requires
activation of PI3-kinase and MAPK/Erk1,2. For this purpose
the cells were treated either with 20 lM LY294002, which
inhibits catalytic part of PI3-kinase [35] or with 20 lM
PD98059, an inhibitor of MEK1,2, upstream to Erk1,2 [36] be-
fore addition of 10 nM 1,25D. In both cases the appearance of
nuclear VDR was inhibited, without increase in cytosolic com-partment (Fig. 3a and b), what shows that signal for new pro-
tein translation was lacking. This eﬀect was not observed for
another nuclear receptor, that is ERa. In HL60 cells this inhi-
bition was well visible after relatively short exposure to inhib-
itors (2–3 h), while in THP-1 cells the inhibition was more
pronounced after longer exposure time (24 h). This diﬀerence
could be due to the fact that the basal Erk1,2 kinase activity
in THP-1 cells is more than double of that in HL60 cells
[37]. The observation described here explains why activations
of PI3-kinase and of MAPK/Erk1,2 are important and neces-
sary for 1,25D-induced diﬀerentiation of myeloid leukemia
cells. Since PD98059 has been shown not to be completely spe-
ciﬁc, and it is known at present that it inhibits also kinase sup-
pressor of Ras (KSR-1), another interpretation of our results
should be taken under consideration [38]. However, as activa-
tion of KSR-1 can be seen at later steps of 1,25D induced dif-
ferentiation [33], while activation of Erk1,2 is very rapid [39],
we think that in this case inhibition of Erk1,2 is more likely
to be the reason of the observed eﬀects. Some light into the
nature of a crosstalk between VDR and intracellular signaling
pathways may be put by our control experiments. There ap-
peared that in the cells treated with PD98059 and LY294002
alone cytosolic content of VDR was lowered in comparison
with control cells (Fig. 3c). This eﬀect was speciﬁc for VDR
protein, because ERa was expressed on a comparable level
in all samples, in spite of the treatment applied. Since the initial
level of VDR protein was lowered by kinase inhibitors, 1,25D
added later did not have enough receptor to bind. Thus VDR-
mediated responses were diminished in cells pretreated with ki-
nase inhibitors. This observation suggests also that transcrip-
tion of VDR gene in response to 1,25D is mediated by
liganded VDR.
3.4. Expression and nuclear translocation of VDR is not
SB203580-dependent
In contrast to PI3-kinase and MAPK/Erk1,2, MAPK/p38
kinase is a negative regulator of 1,25D induced leukemia cell
diﬀerentiation [10]. In order to ﬁnd out if it regulates vitamin
D signaling downstream or upstream of VDR translation,
HL60 cells were pretreated with p38 inhibitor, 10 lM
Treatment control 10nM 1,25D SB + 1,25D 
Fraction C/M N C/M N C/M N
Lane 1 2 3 4 5 6
VDR →
β-actin →
Fig. 4. Expression and nuclear translocation of VDR is not regulated
by p38. HL60 cells were treated for 2 h with 10 nM 1,25D. One sample
was pretreated for 1 hour with 10 lM SB203580. The cells were
fractionated into cytoplasm (C/M) and nuclei (N). b-Actin was
detected as a loading and transfer control.
Treatment control 10nM 1,25D
20μM 
LY+1,25D
20μM 
PD+1,25D 
Fraction C/M N C/M N C/M N C/M N 
Lane 1 2 3 4 5 6 7 8
VDR →
β-actin →
Treatment control 10nM 1,25D
20μM 
PD+1,25D
20μM 
LY+1,25D 
Fraction C/M N C/M N C/M N C/M N 
Lane 1 2 3 4 5 6 7 8
VDR →
β-actin →
Treatment control 10nM 1,25D
20μM 
PD98059 
20μM 
LY294002
Fraction C/M N C/M N C/M N C/M N
Lane 1 2 3 4 5 6 7 8
VDR →
β-actin →
ER α →
a
b
c
Fig. 3. PI3-kinase and Erk1,2-dependent expression and nuclear
translocation of VDR. The cells were treated with 10 nM 1,25D for
2 h (HL60; a) or for 24 h (THP-1; b). One sample was preincubated
with 20 lM LY294002 and one with 20 lM PD98059 for 1 h before
addition of 1,25D. In separate samples HL60 cells were incubated with
either 20 lM LY294002 or 20 lM PD98059 for 3 h (c). The cells were
fractionated into cytoplasm (M/C) and nuclei (N). b-Actin was
detected as a loading and transfer control.
Treatment control 10nM 1,25D 1,25D + LB
Fraction M/C N M/C N M/C N
Lane 1 2 3 4 5 6
VDR →
β-actin →
Fig. 5. Nuclear export of VDR is not inhibited by leptomycin B. HL60
cells were treated for 3 h with 10 nM 1,25D. One sample was then
incubated with 5 ng/ml of Leptomycin B (LB) for last 2 h. The cells
were fractionated into cytoplasm (C/M) and nuclei (N). b-Actin was
detected as a loading and transfer control.
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did not see any increase in VDR expression in the cells treated
with SB203580, we suppose that p38 is activated downstream
from VDR translation (Fig. 4). Possibly the feedback between
MAPK/Erk1,2 and MAPK/p38, which was reported before
[10] is generated by a VDR-mediated pathway.
3.5. Export of VDR from the cell nucleus is leptomycin
B-independent
Most proteins localized in the cell nucleus may be trapped
there using leptomycin B, a speciﬁc inhibitor of exportin 1
[41]. This is rather controversial if nuclear receptors are ex-
ported from the nuclei in exportin 1-dependent manner. Some
researchers proved that nuclear export of glucocorticoid recep-
tor is not mediated by exportin 1, and they claimed that nucle-
ar receptors do not contain leucine-rich nuclear export signals
(NES) [42], while others showed that addition of leptomycin B
changes intracellular distribution of VDR/RXR complex and
traps it inside the cell nucleus [25]. Since these controversial
results were obtained using transfected cell line models withoverexpressed nuclear receptors, we wanted to verify if in
untransfected leukemia cells nuclear VDR is exported back
to the cytosol in an exportin 1-dependent manner. We found
that 5 ng/ml of leptomycin B did not change VDR content in
the nuclei of HL60 cells treated with 1,25D (Fig. 5). This result
suggests that either VDR is exported from the nucleus in an
exportin 1-independent manner, or that nucleus is a degrada-
tion site for VDR protein, since nuclear transport of new
VDR particles must be equilibrated by its degradation.
3.6. Subcellular localization of VDR in leukemia cells
In our cell fractionation experiments the cells were divided
into two big compartments: cytoplasm and nuclei. Next we
wanted to determine a subcellular localization of this protein
in a more detailed fashion using confocal microscopy. For this
purpose we needed to immobilize the cells on the surface of the
coverslips coated with poly-L-lysine. As HL60 cells did not
adhere to the surface, these experiments were performed using
only THP-1 cells. As presented in Fig. 6, in untreated cells
localization of VDR was relatively uniform in cytosol and
nucleosol, with some accumulation at the plasma membrane
vicinity. In 1,25D-treated THP-1 cells nuclear expression of
VDR grew in a concentration-dependent manner. There was
also increase of this protein expression at the plasma mem-
brane neighborhood. The submembrane portion of VDR colo-
calized well with polymerized actin, but not with globular actin
(data not shown). It has been reported in past that VDR is
present in caveolin enriched regions of plasma membrane
[43] and it has been suggested that this portion of VDR is
responsible for activation of ‘‘rapid’’ signaling in the cells ex-
posed to 1,25D. To further study if VDR protein is attached
to any membrane protein, we fractionated THP-1 cells into
membranes (M), cytosol (C) and nuclei (N). As presented in
Fig. 6. Intracellular localization of VDR. THP-1 cells were untreated or treated with 1,25D for 12 h. The cells were stained with anti-VDR antibody
(red) and with phalloidin, which binds to F-actin (green). First row panels show F-actin staining, second row panels show VDR staining and third
row panels show both stainings merged. Fourth row panels present magniﬁcation of single cell from the picture above.
Treatment 10nM 1,25D
Fraction M C N M C N
Lane 1 2 3 4 5 6
VDR →
β-actin →
control
Fig. 7. VDR is localized only in cell cytosol and nucleus. THP-1 cells
were either untreated or treated with 10 nM 1,25D for 2 h. The cells
were fractionated into membranes (M) cytosol (C) and nuclei (N). b-
Actin was detected as a loading and transfer control.
E. Gocek et al. / FEBS Letters 581 (2007) 1751–1757 1755Fig. 7, VDR leaked out of the cells together with cytosol, what
shows that it was neither localized inside plasma membrane,
nor attached to membrane proteins.
The fact that VDR is a main intracellular mediator of 1,25D
activities is rather unquestioned, but the existence of other
components of 1,25D signaling pathways is also widely ac-
cepted [44]. It is still unclear how ‘‘rapid’’ signaling of 1,25D
is generated, hence various possibilities exist. One hypothesis
proposes existence of a separate membrane receptor for
1,25D, similar to growth factor receptors [45], and the second
says that portion of VDR which is localized in caveolin-rich re-
gions of the plasma membrane generates intracellular signals
[43]. There is also one more possible mechanism to be consid-
ered. It has been shown recently that megalin [46] and cubilin
[47] are responsible for the renal uptake of vitamin D com-
pounds bound to vitamin D binding protein from blood, using
an endocytic pathway. It is also well documented that endocy-
ted receptors activate intracellular signaling pathways, whathelps them to ﬁne-tune precise cellular responses [48]. There
could exist receptors for the vitamin D uptake in myeloid cells,
similar to these in kidney cells, which can generate rapid
intracellular signaling connected with their ligation and endo-
cytosis. Such possibility has been recently supported by the
MEK 1/2 
Erk 1/2 
FCS
MKK 3/6 
p38 
MEKKs Raf-1 
VDR
VDR 
differentiation
related
genes
VDR 
K
S
R
1 
Ras 
PI3-K
Src1,25D 
Fig. 8. Proposed pathways of 1,25D-dependent signaling in diﬀerentiation of myeloid leukemia cells.
1756 E. Gocek et al. / FEBS Letters 581 (2007) 1751–1757observation of megalin mediated endocytosis of vitamin D
binding protein in human mammary cells [49]. Nevertheless
we show in this paper that rapid activation of signal transduc-
tion pathways, which is necessary for cellular eﬀects of 1,25D,
comes not only from 1,25D itself, but also from other factors
which activate intracellular signalling. Therefore, we want to
suggest that signals, which come from endocyted 1,25D can
crosstalk with the signals generated by growth factors con-
tained in fetal calf serum. We propose to slightly modify the
earlier proposal of hypothetic pathways of 1,25D-induced
monocytic diﬀerentiation [50], and we present it in Fig. 8.
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